Icon (ICLR) Income from Non-Controlling Interests (2019 - 2026)
Icon's (ICLR) quarterly Income from Non-Controlling Interests came in at $19.4 million in Q2 2026, up 25.94% year-over-year from $15.4 million in Q2 2025, and down 57.92% quarter-over-quarter from $46.2 million in Q3 2025.
Analysis
Icon (ICLR) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Icon (ICLR) has reported Income from Non-Controlling Interests for 8 consecutive years, with $19.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income from Non-Controlling Interests rose 25.94% year-over-year to $19.4 million in Q2 2026; TTM through Jun 2026 was $93.4 million, a 105.39% increase from a year earlier, with the FY2024 full-year figure at $45.9 million, down 17.6% from the prior year.
- Income from Non-Controlling Interests was $19.4 million for Q2 2026 at Icon, down from $46.2 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $46.2 million in Q3 2025 and troughed at $4.7 million in Q4 2024.
- A 5-year average of $16.5 million and a median of $15.2 million in 2022 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests plunged 47.86% in 2023 and jumped 254.28% in 2025, its largest moves.
- Over 5 years, Income from Non-Controlling Interests stood at $15.0 million in 2022, then slumped by 47.86% to $7.8 million in 2023, then tumbled by 40.25% to $4.7 million in 2024, then surged by 885.51% to $46.2 million in 2025, then tumbled by 57.92% to $19.4 million in 2026.
- The last three Income from Non-Controlling Interests figures came in at $19.4 million (Q2 2026), $46.2 million (Q3 2025), and $15.4 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 2.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | - |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 19.44 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 722,000.00 |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | - |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | - |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | - |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.44 Mn |
| Sep 30, 2025 | 46.19 Mn |
| Jun 30, 2025 | 15.43 Mn |
| Mar 31, 2025 | 12.29 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 13.04 Mn |
| Jun 30, 2024 | 14.96 Mn |
| Mar 31, 2024 | 13.18 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Sep 30, 2023 | 16.47 Mn |
| Jun 30, 2023 | 16.60 Mn |
| Mar 31, 2023 | 14.76 Mn |
| Dec 31, 2022 | 15.05 Mn |
| Sep 30, 2022 | 16.73 Mn |
| Jun 30, 2022 | 18.89 Mn |
| Mar 31, 2022 | 19.22 Mn |
| Dec 31, 2021 | 19.41 Mn |
| Sep 30, 2021 | 26.36 Mn |
| Jun 30, 2021 | 8.80 Mn |
| Mar 31, 2021 | 6.84 Mn |